Story perspectives

FDA Approves Journavx for Acute Pain Amid Cost Concerns

10/13/2025

50 11

Summary

Story summary

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) on January 30, 2025 for moderate to severe acute pain, but not for chronic pain.
As a result of the approval, patients may pay $480–$520 for 30 pills, and insurance may not cover extended use.
Alka-Seltzer is highlighted as an effective heartburn remedy, with effervescent tablets providing quick relief.
The Peoples Pharmacy website offers the eGuide to Overcoming Digestive Disorders.

1 of 1

Story summary

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) on January 30, 2025 for moderate to severe acute pain, but not for chronic pain.
As a result of the approval, patients may pay $480–$520 for 30 pills, and insurance may not cover extended use.
Alka-Seltzer is highlighted as an effective heartburn remedy, with effervescent tablets providing quick relief.
The Peoples Pharmacy website offers the eGuide to Overcoming Digestive Disorders.